10-Q

$AMGN · Amgen Inc.

November 4, 2026 · AI-analyzed SEC filing · Verify material figures against the official SEC.gov filing

Amgen Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026. The filing contains the company’s condensed consolidated financial statements and related notes for the third quarter and first nine months of 2026. The extracted data includes revenue and segment disclosures broken down by product, with separate figures for U.S. and non-U.S. sales across several key products, including Repatha, Prolia, EVENITY, TEPEZZA, Enbrel, and Otezla.

The filing also presents balance sheet, income statement, cash flow, and equity rollforward information, along with segment reporting and other standard quarterly disclosures. No specific dollar amounts or year-over-year changes are provided in the extracted text, so the core event is simply the submission of Amgen’s quarterly report covering the period ended September 30, 2026.

Get filings like this before the market reacts.

Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.

Start your free trial →